Eli Lilly, the maker of blockbuster weight loss and diabetes drugs Zepbound and Mounjaro, said it will invest an additional $27 billion to build four new manufacturing plants in the United States, shoring up domestic manufacturing as President Donald Trump threatens new tariffs on pharmaceuticals.

Eli Lilly plans to spend at least $27bn to build four new manufacturing plants in the United States, the drugmaker has said as it grapples with the threat of drug import duties from the Trump administration.

Whatever you think of Donald Trump’s tariff policies, one fact stands out: companies are looking to invest more in the United States. They want to avoid the negative impacts of tariffs on their business.

Pharmaceutical giant expects the move will create 3,000 high-skilled jobs and provide work for approximately 10,000 construction workers.

Eli Lilly (NYSE:LLY) announced plans to more than double its investments in domestic medicine production to over $50B on Wednesday, amid President Donald Trump’s moves to impose tariffs to encourage local manufacturing.

(Reuters) -Eli Lilly plans to spend at least $27 billion to build four ... The announcement comes less than a week after U.S. President Donald Trump met with chief executives from major drugmakers, including Lilly CEO David Ricks, to discuss industry ...

The company is doubling plans for capital spending on U.S. factories as President Donald Trump pressures the pharma industry to reshore drug production.

It comes as companies work to build goodwill with Trump, who has emphasized reshoring manufacturing to the U.S. and reducing reliance on foreign supply chains.

Eli Lilly is doubling its U.S. manufacturing investment since 2020 as it seeks to produce more drugs domestically. Its latest investment is to the tune of $27 billion.

A federal judge has effectively ended the ability of compounding pharmacies to make their own copies of Eli Lilly’s weight loss and diabetes drugs.

Eli Lilly plans to spend at least $27bn to build ... The announcement comes less than a week after US President Donald Trump met with chief executives from major drugmakers, including Lilly ...